Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia

Creative Commons License

ÖZASLAN E., EROĞLU E., GÖK K., Senel S., BALDANE S., Akyol L., ...More

ROMANIAN JOURNAL OF INTERNAL MEDICINE, vol.53, no.3, pp.282-285, 2015 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 53 Issue: 3
  • Publication Date: 2015
  • Doi Number: 10.1515/rjim-2015-0037
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.282-285
  • Keywords: capecitabine, drug induced lupus erythematosus, thrombocytopenia
  • Ondokuz Mayıs University Affiliated: Yes


yDrug induced lupus erythematosus (DILE) is a syndrome that is formed by lupus-like symptoms and laboratory characteristics. Capecitabine is an orally administered tumor-selective fluoropyrimidine that acts as a prodrug of 5-Fluorouracil and bevacizumab is an antivascular endothelial growth factor (anti-VEGF) antibody, both are used for the treatment of patients with colorectal cancer. Herein we report the first case of DILE in a 68-year-old woman who presented with arthralgia, myalgia and prolonged thrombocytopenia after receiving capecitabine and bevacizumab combination treatment as palliative treatment for metastatic colon cancer. Platelet levels were increased and joint complaints disappeared in the first week of hydroxychloroquine and methylprednisolone treatment after chemotherapy had been discontinued. In conclusion, physicians should be alert to the possibility of DILE in patients presenting with thrombocytopenia under a capecitabine and bevacizumab chemotherapy regimen.